Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
Picking up the Lilly cast-off might not have been an easy win for Provention after all.